

Online Resource 1

Article title: Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Journal: *Clinical Rheumatology*

Authors: Désirée van der Heijde, Patrick Durez, Georg Schett, Esperanza Naredo, Mikkel Østergaard, Gabriella Meszaros, Francesco De Leonardis, Inmaculada de la Torre, Pedro López-Romero, Douglas Schlichting, Eric Nantz, Roy Fleischmann

Affiliation of corresponding author: Leiden University Medical Center, Leiden, The Netherlands, email address: mail@dvanderheijde.nl

Legend: Heatmaps showing individual DAS28-hsCRP responses to treatment in
(a) DAS28-Group A (sustained DAS28-hsCRP ≤ 3.2 at weeks 16, 20 and 24) and
(b) DAS28-Group B (DAS28-hsCRP > 3.2 or missing data at any of weeks 16, 20 and 24).

Bari baricitinib, *base* baseline, *DAS28* Disease Activity Score for 28-joint counts, *hsCRP* high-sensitivity C-reactive protein, *MTX* methotrexate, *NA* not available, *w* week

DAS28-hsCRP colour codes: ■ ≤ 2.6 ■ > 2.6 to ≤ 3.2 ■ > 3.2 to ≤ 5.1 ■ > 5.1 ■ NA

